Funding for this research was provided by:
National Institutes of Health
Cancer Research Institute
Melanoma Research Alliance
Text and Data Mining valid from 2018-05-18
Received: 27 December 2017
Accepted: 13 February 2018
First Online: 18 May 2018
Ethics approval and consent to participate
: The three adjuvant vaccine trials were conducted in accordance with all accepted standards for the ethical conduct of human subjects research; all three were approved by the NYU IRB, and all patients provided informed consent at the time of enrollment. The NYU melanoma registry is approved by the NYU IRB for the prospective collection of demographic, clinical, and pathologic data as well as biospecimens for research purposes. The present retrospective study was approved by the NYU IRB (s15–01258), which granted a waiver of informed consent.
: All patients consented to participate in either an adjuvant vaccine trial or the NYU melanoma registry.
: The authors declare that they have no competing interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.